Microglial dysfunction in Alzheimer's disease: Mechanisms, emerging therapies, and future directions

Mahir Azmal1, Jibon Kumar Paul1, Fatema Sultana Prima1

  • 1Department of Biochemistry and Molecular Biology, Shahjalal University of Science and Technology, Sylhet 3114, Bangladesh.

PubMed

Insights

Microglia, the brain's immune cells, shift from protective to harmful roles in Alzheimer's disease (AD). Targeting their inflammatory pathways offers new therapeutic avenues for AD treatment.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Alzheimer's disease (AD) involves amyloid-beta (Aβ) plaques, tau tangles, and neuroinflammation.
  • Microglia, the brain's immune cells, are central to AD pathogenesis.
  • Microglial dysfunction transitions from neuroprotection to detrimental inflammation.

Purpose of the Study:

  • To explore molecular mechanisms of microglial dysfunction in AD.
  • To emphasize key inflammatory pathways (NF-κB, MAPK, TLR4) driving neuroinflammation.
  • To examine therapeutic strategies targeting microglial activity.

Main Methods:

  • Review of molecular mechanisms in microglial dysfunction.
  • Analysis of inflammatory signaling pathways (NF-κB, MAPK, TLR4).
  • Examination of emerging therapeutic strategies for AD.

Main Results:

  • Prolonged microglial activation promotes a pro-inflammatory state.
  • Inflammatory pathways release cytokines (IL-1β, TNF-α, IL-6), exacerbating neuroinflammation.
  • Genetic (APOE4) and environmental factors modulate microglial activity.

Conclusions:

  • Modulating microglial activity is a promising therapeutic strategy for AD.
  • Longitudinal studies are crucial for understanding microglial roles in disease progression.
  • Personalized medicine approaches are essential for effective AD treatment.